Company intelligence / Profile preview
Stiefel Laboratories
- Ownership
- Private
- Employees
- ~3000
- Development stage
- Other
Overview
Stiefel was the world’s largest independent dermatology pharmaceutical company prior to its 2009 acquisition by GlaxoSmithKline. It developed and marketed a broad portfolio of prescription and OTC products for major skin conditions including acne and psoriasis. Its leading products included Duac for acne, Olux E for dermatitis, Soriatane for severe psoriasis; it also pioneered benzoyl peroxide use in acne treatment with Sulfoxyl Lotion. At the time of acquisition by GSK in 2009 for $2.9 billion plus contingent payments ($3.6 billion total potential value), annual sales were approximately $900 million.
- Therapeutic areas
- DermatologyOncology
- Modalities
- Small moleculeBiologic (topical and oral dermatological therapies)
- Industry
- Biotech
Drug pipeline
15 assets14 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Stiefel Laboratories.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Stiefel Laboratories.